Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TAS0313 |
| Synonyms | |
| Therapy Description |
TAS0313 is a cancer vaccine composed of 12 cytotoxic T-cell epitope peptides derived from tumor-associated antigens, which potentially induces antitumor immune activity (PMID: 33615628, PMID: 38060587). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TAS0313 | TAS-0313|TAS 0313 | TAS0313 is a cancer vaccine composed of 12 cytotoxic T-cell epitope peptides derived from tumor-associated antigens, which potentially induces antitumor immune activity (PMID: 33615628, PMID: 38060587). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|